Johnson & Johnson (JNJ)
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.
Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pharma tariffs unlikely to hit earnings before 2026, analysts say
Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Both JNJ & PFE expect their sales and profits to improve in 2025.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
S&P 500 Gains and Losses Today: Johnson & Johnson Drops as Judge Rejects Liability Settlement
Major U.S. equities indexes finished the first trading day of the second quarter mixed.
Why Johnson & Johnson Stock Is Sinking Today
Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.
Johnson & Johnson shares fall as US judge rejects $10B talc settlement plan
Johnson & Johnson (NYSE:JNJ) shares moved almost 5% lower after a US bankruptcy judge rejected its $10 billion settlement proposal which sought to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston, dismissed the bankruptcy claim filed by J&J subsidiary Red River Talc, citing flaws in the voting process for personal injury claimants.
Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits
A judge rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its products caused ovarian cancer.
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected
J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan
Johnson & Johnson stock slumped Tuesday after a judge rejected its $10 billion proposal to settle thousands of talc-tied lawsuits. The post J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan appeared first on Investor's Business Daily.
